Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug 12:61:101660.
doi: 10.1016/j.lanwpc.2025.101660. eCollection 2025 Aug.

What is the role of common sense oncology in the Western Pacific?

Samuel Xavier Stevens  1   2   3 , Christopher G C A Jackson  4   5 , Deme Karikios  2   6
Affiliations
Review

What is the role of common sense oncology in the Western Pacific?

Samuel Xavier Stevens et al. Lancet Reg Health West Pac. .

Abstract

Established in 2023, Common Sense Oncology (CSO) is a grass roots initiative uniting cancer clinicians, policymakers, academics, patients and their advocates that calls for a 'recalibration' of cancer care to focus on outcomes that matter to patients. CSO emphasises treatments that substantially improve survival and quality of life, and advocates for equitable global access to effective cancer therapies. This article examines the potential of CSO principles to improve cancer care in the Western Pacific, a geographically and culturally diverse region that shoulders one-third of the global cancer burden. We review early progress of CSO working groups and identify regional challenges, such as engaging diverse membership, fostering local change, and evaluating impact. Unique regional strengths, such as longstanding cooperative trial group and China's growing influence in global drug development, are highlighted.

Keywords: Cancer care; Clinical trials; Common Sense Oncology (CSO); Health equity; Healthcare costs; Healthcare policy; Value; Western Pacific.

PubMed Disclaimer

Conflict of interest statement

SS is employed by Common Sense Oncology as a Clinical Research Fellow in Cancer Policy. DK is a member of the Common Sense Oncology Leadership Group. He discloses payment/honoraria from Merck Sharp & Dohme Pty Ltd, Roche, AbbVie, AstraZeneca Australia, and Takeda Pharmaceuticals Australia Pty Ltd. CJ is a member of the Common Sense Oncology Leadership Group.

Similar articles

See all similar articles

References

    1. Ferlay J.L.M., Ervik M., Lam F., et al. International Agency for Research on Cancer; Lyon, France: 2024. Global cancer observatory: cancer tomorrow.https://gco.iarc.who.int/tomorrow Available from:
    1. Booth C.M., Sengar M., Goodman A., et al. Common Sense oncology: outcomes that matter. Lancet Oncol. 2023;24(8):833–835. - PubMed
    1. Wolchok J.D., Chiarion-Sileni V., Gonzalez R., et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 2021;40(2):127–137. - PMC - PubMed
    1. Schadendorf D., Larkin J., Wolchok J., et al. Health-related quality of life results from the phase III CheckMate 067 study. Eur J Cancer. 2017;82:80–91. - PMC - PubMed
    1. Michaeli D.T., Michaeli T. Overall survival, progression-free survival, and tumor response benefit supporting initial US food and drug administration approval and indication extension of new cancer drugs, 2003-2021. J Clin Oncol. 2022;0(0) JCO.22.00535. - PubMed

LinkOut - more resources